natgillin/translations-raw huggingface dataset:
In most subjects with severe hepatic impairment, the clearance of levetiracetam was reduced by more than 50% due to a concomitant renal impairment (see section 4.2).
Pri večini preiskovancev s hudo okvaro jeter se je očistek levetiracetama zaradi sočasne okvare ledvic zmanjšal za več kot 50 % (glejte poglavje 4.2).
Before starting the measuring procedure make sure that the transparent dosing body of the syringe as well as the white plunger are in the bottom most position.
Preden začnete postopek merjenja, se prepričajte, da sta prozorno telo odmerne brizge in njen beli bat v najnižjem položaju.
Hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients listed in section 6.1.
Preobčutljivost za zdravilno učinkovino, kakšen drug pirolidonski derivat ali katero od pomožnih snovi, navedeno v poglavju 6.1.
• a more severe form of rash causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis);
• hujšo obliko izpuščaja, ki povzroči luščenje kože na več kot 30 % telesne površine (toksična epidermalna nekroliza)
In addition, levetiracetam does not affect the in vitro glucuronidation of valproic acid.
Poleg tega levetiracetam in vitro ne vpliva na glukuronidacijo valprojske kisline.
The primary measure of effectiveness was the responder rate (percent of patients with ≥ 50% reduction from baseline in average daily partial onset seizure frequency) assessed by a blinded central reader using a 48-hour video EEG.
Primarna mera učinkovitosti je bil delež odzivnih bolnikov (bolnikov, ki so dosegli ≥ 50 % zmanjšanje povprečne dnevne pogostnosti napadov parcialnega izvora), kot ga je ocenil slepljen centralni pregledovalec z uporabo 48-urnega video EEG.
Dose in adults and adolescents (12 to 17 years):
Odmerek pri odraslih in mladostnikih (od 12 do 17 let):
These data are supplemented with the use of levetiracetam in corresponding open-label extension studies, as well as post-marketing experience.
Ti podatki so dopolnjeni s podatki iz ustreznih odprtih, razširjenih študij o uporabi levetiracetama ter s postmarketinškimi podatki.
After oral administration the bitter taste of levetiracetam may be experienced.
Po peroralnem dajanju se lahko okusi grenak okus levetiracetama.
Reykjavíkurvegur 76-78 220 Hafnarfjörður Iceland
Reykjavíkurvegur 76-78
The oral solution may be diluted in a glass of water or baby's bottle and may be taken with or without food.
Način uporabe Peroralno raztopino je mogoče razredčiti v kozarcu vode ali dojenčkovi steklenički; zdravilo se lahko vzame s hrano ali brez hrane.
• swelling of the face, lips, tongue and throat (Quincke's oedema);
• otekanje obraza, ustnic, jezika in žrela (Quinckejev edem)
Elderly (65 years and older)
Posebne skupine bolnikov Starejši (65 let in več)
• sudden decrease in kidney function;
• nenadno zmanjšanje delovanja ledvic
He/she may decide if your dose should be adjusted.
Zdravnik se lahko odloči, da vam bo odmerek prilagodil.
The extent of absorption is dose-independent and is not altered by food.
Obseg absorpcije ni odvisen od odmerka; hrana ga ne spremeni.
The efficacy analysis consisted of 109 patients who had at least 24 hours of video EEG in both baseline and evaluation periods.
Analiza učinkovitosti je zajela 109 bolnikov, ki so tako izhodiščno kot med obdobjem ocenjevanja imeli vsaj 24-urni video EEG.
For adults and children aged 4 years and older
Za odrasle in otroke, stare 4 leta in več
• rhabdomyolysis (breakdown of muscle tissue) and associated blood creatine phosphokinase increase.
• rabdomioliza (razpad mišičnega tkiva) in z njo povezano zvišanje kreatin fosfokinaze v krvi.
However, data suggested a 20 % higher levetiracetam clearance in children taking enzymeinducing antiepileptic medicinal products.
So pa podatki pokazali 20 % večji očistek levetiracetama pri otrocih, zdravljenih z antiepileptičnimi zdravili, ki inducirajo encime.
This binding site is the synaptic vesicle protein 2A, believed to be involved in vesicle fusion and neurotransmitter exocytosis.
To vezavno mesto je sinaptična vezikularna beljakovina 2A, domnevno vključena v fuzijo veziklov in eksocitozo nevrotransmiterjev.
Push the plunger in slowly to the graduation mark corresponding to the quantity in milliliters (ml) prescribed by your doctor (Figure 7).
Bat počasi potisnite do odmerne oznake, ki ustreza količini v mililitrih (ml), kakršno je predpisal zdravnik (slika 7).
Levetiracetam Actavis Group may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy.
Zdravilo Levetiracetam Actavis Group vam lahko poslabša sposobnost upravljanja vozil in strojev, ker lahko povzroči zaspanost.
In the population pharmacokinetic analysis conducted in patients from 1 month to 16 years of age, body weight was significantly correlated to apparent clearance (clearance increased with an increase in body weight) and apparent volume of distribution.
V populacijski farmakokinetični analizi pri bolnikih, starih od 1 mesec do 16 let, je telesna masa statistično značilno korelirala z navideznim očistkom (očistek se je povečeval z naraščanjem telesne mase) in navideznim volumnom porazdelitve.
This presentation should be prescribed for children aged 4 years and older, adolescents and adults.
To pakiranje je treba predpisati otrokom, starim 4 leta ali več, mladostnikom in odraslim.
Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels.
Poročali so, da sočasna uporaba levetiracetama in metotreksata zmanjša očistek metotreksata, zaradi česar je koncentracija metotreksata v krvi povišana/podaljšana do potencialno toksična.
In vitro studies show that levetiracetam affects intraneuronal Ca2+ levels by partial inhibition of N-type Ca2+ currents and by reducing the release of Ca2+ from intraneuronal stores.
Študije in vitro so pokazale, da levetiracetam vpliva na raven Ca2+ v nevronu z delnim zavrtjem tokov Ca2+ tipa N in z zmanjšanjem sproščanja Ca2+ iz zalog v nevronu.
The content of the syringe can also be emptied in a glass of water or baby´s bottle.
Vsebino brizge lahko izpraznite tudi v kozarec vode ali v dojenčkovo stekleničko.
In addition, 101 infants aged less than 12 months have been exposed in a post authorization safety study.
Poleg tega je bilo v obdobju po začetku trženja zdravila, 101 dojenčkov, mlajših od 12 mesecev, vključenih v varnostno študijo.
More than half of the subjects remained seizure free for 12 months (56.6% and 58.5% of subjects on levetiracetam and on carbamazepine CR respectively).
Več kot polovica preiskovancev je ostala brez napadov 12 mesecev (56,6 % prejemnikov levetiracetama in 58,5 % prejemnikov karbamazepina CR).
Levetiracetam induces seizure protection in a broad range of animal models of partial and primary generalised seizures without having a pro-convulsant effect.
Levetiracetam zavaruje pred napadi v širokem spektru živalskih modelov parcialnih in primarno generaliziranih napadov in ne deluje prokonvulzivno.
Management of overdose
Obvladovanje prevelikega odmerjanja
Nevertheless, the concentration of this metabolite remains low.
Kljub temu ostane koncentracija primarnega presnovka majhna.
Acute kidney injury
Akutna poškodba ledvic
After an acute overdose, the stomach may be emptied by gastric lavage or by induction of emesis.
Po akutnem prevelikem odmerjanju je mogoče želodec izprazniti z izpiranjem želodca ali sprožitvijo bruhanja.
• a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome);
• široko razširjen izpuščaj z mehurčki in luščenjem kože, še posebej okoli ust, nosu, oči in v predelu spolovil (Stevens-Johnsonov sindrom)
The safety profile of levetiracetam is generally similar across age groups (adult and paediatric patients) and across the approved epilepsy indications.
Varnostni profil levetiracetama je v splošnem podoben v vseh starostnih skupinah (odrasli in pediatrični bolniki) in pri vseh odobrenih indikacijah za zdravljenje epilepsije.
• uncontrollable muscle spasms affecting the head, torso and limbs, difficulty in controlling movements, hyperkinesia (hyperactivity);
• nekontrolirani mišični spazmi, ki prizadanejo glavo, trup in okončine, težave pri nadzoru gibanja, hiperkinezija (hiperaktivnost)
Therefore, patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered.
Bolnike je zato treba kontrolirati glede znakov depresije in/ali samomorilnega razmišljanja ali vedenja;
Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite, but not of levetiracetam.
Za probenecid (500 mg štirikrat na dan), ki blokira ledvično tubularno sekrecijo, je dokazano, da zavre ledvični očistek primarnega presnovka, ne pa levetiracetama.
The primary metabolite is inactive.
Primarni presnovek ni aktiven.
For children with renal impairment, levetiracetam dose needs to be adjusted based on the renal function as levetiracetam clearance is related to renal function.
Otrokom z okvaro ledvic je treba odmerek levetiracetam prilagoditi glede na delovanje ledvic, kajti očistek tega zdravila je povezan z delovanjem ledvic.
Peak plasma concentrations (Cmax) are achieved at 1.3 hours after dosing.
Največja koncentracija v plazmi (Cmax) je dosežena 1,3 ure po odmerku.
Take the oral solution following your doctor's instructions.
Peroralno raztopino jemljite po zdravnikovih navodilih.
• Levetiracetam Actavis Group is used as a chronic treatment.
• Zdravilo Levetiracetam Actavis Group se uporablja za kronično zdravljenje.
Co-administration with any substrate for alcohol dehydrogenase such as ethanol may induce serious adverse effects in neonates.
Sočasno jemanje katerega koli substrata alkoholdehidrogenaze lahko povzroči hude neželene učinke pri novorojenčkih.
Push the tip of the syringe into the adaptor opening.
Potisnite konico brizge v odprtino nastavka.
(impaired coordinated movements), paraesthesia (tingling), disturbance in attention (loss of concentration);
(motena usklajenost mišičnih gibov), parestezija (mravljinčenje), motnje pozornosti (izguba koncentracije)
Dose recommendations for infants from 6 months of age, children and adolescents:
Priporočila za odmerjanje pri dojenčkih od 6. meseca starosti, otrocih in mladostnikih:
• anorexia (loss of appetite);
• anoreksija (izguba teka)
The contents of the syringe can also be given directly from the syringe into the mouth or emptied onto a spoon (Figure 3).
Vsebino brizge si lahko daste tudi neposredno v usta ali jo izpraznite na žlico (slika 3).
Dose adjustment is not required.
Odmerka ni treba prilagoditi.
Cases of encephalopathy generally occurred at the beginning of the treatment (few days to a few months) and were reversible after treatment discontinuation.
Primeri encefalopatije so se običajno pojavili na začetku zdravljenja (od nekaj dni do nekaj mesecev)
• flu-like symptoms and a rash on the face followed by an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS]);
• gripi podobne simptome in izpuščaj na obrazu, ki se v nadaljevanju razširi in ga spremlja visoka temperatura, zvišane vrednosti jetrnih encimov pri krvnih testih in povečanje števila določenega tipa belih krvnih celic (eozinofilija) ter povečane bezgavke (reakcija na zdravilo z eozinofilijo in sistemskimi simptomi [DRESS]
• symptoms such as low urine volume, tiredness, nausea, vomiting, confusion and swelling in the legs, ankles or feet, as this may be a sign of sudden decrease of kidney function;
• simptome kot so nizek volumen urina, utrujenost, slabost, bruhanje, zmedenost in otekanje nog, gležnjev ali stopal saj so lahko to znaki nenadnega zmanjšanja delovanja ledvic
In patients with severe hepatic impairment, the creatinine clearance may underestimate the renal insufficiency.
Pri bolnikih s hudo okvaro jeter lahko očistek kreatinina podceni stopnjo odpovedi ledvic.
• If you notice any slow down in the growth or unexpected puberty development of your child,
• Če pri otroku opazite upočasnitev rasti ali nepričakovan pojav pubertete, se posvetujte z zdravnikom.
Levetiracetam is a highly soluble and permeable compound.
Levetiracetam je zelo topna in permeabilna spojina.
Should your doctor decide to stop your Levetiracetam Actavis Group treatment, he/she will instruct you about the gradual withdrawal of Levetiracetam Actavis Group.
Če se bo vaš zdravnik odločil za prekinitev zdravljenja z zdravilom Levetiracetam Actavis Group, vam bo dal napotke o postopni ukinitvi zdravila Levetiracetam Actavis Group.
To measure the dosing quantity, use one hand to hold the dosing body and the other hand to pull up the plunger until you reach the graduation mark corresponding to the quantity in milliliters (ml) prescribed by your doctor (Figure 1).
Da boste odmerili potrebni odmerek, z eno roko primite telo odmerne brizge in z drugo roko izvlecite njen bat, dokler ne doseže odmerne oznake, ki ustreza količini v mililitrih (ml), kakršno je predpisal zdravnik (slika 1).
In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection (see section 4.2).
Bolnikom s hudo okvarjenim delovanjem jeter je pred izbiro odmerka priporočljivo oceniti delovanje ledvic (glejte poglavje 4.2).
Levetiracetam 2,000 mg daily did not influence the pharmacokinetics of digoxin and warfarin; prothrombin times were not modified.
Levetiracetam v odmerku 2.000 mg na dan ni vplival na farmakokinetiko digoksina in varfarina; protrombinski čas se ni spremenil.
Monotherapy for adults and adolescents from 16 years of age
Monoterapija za odrasle in mladostnike od 16. leta starosti
The adverse reaction profile presented below is based on the analysis of pooled placebo-controlled clinical trials with all indications studied, with a total of 3,416 patients treated with levetiracetam.
Profil neželenih učinkov, ki je opisan spodaj, temelji na analizi združenih s placebom nadzorovanih kliničnih preskušanj za vse preučevane indikacije, v katerih so z levetiracetamom zdravili 3.416 bolnikov.
Empty the contents of the syringe in a glass of water by pushing down the plunger.
Izpraznite vsebino brizge v kozarec vode, tako da bat potisnete navzdol.
The dose level of 1,800 mg/kg/day induced a marked maternal toxicity and a decrease in foetal weight associated with increased incidence of fetuses with cardiovascular/skeletal anomalies.
Odmerek 1.800 mg/kg/dan je povzročil izrazito toksičnost pri samicah-materah in zmanjšanje telesne mase plodov v povezavi z večjo incidenco plodov s kardiovaskularnimi oziroma skeletnimi anomalijami.
At the beginning of the treatment or at dose increase side effects like sleepiness, tiredness and dizziness may be more common.
Na začetku zdravljenja ali po povečanju odmerka lahko neželeni učinki, npr. zaspanost, utrujenost in omotičnost, so lahko pogostejši na začetku zdravljenja in po povečanju odmerka.
In adults, levetiracetam efficacy has been demonstrated in 3 double-blind, placebo-controlled studies at 1,000 mg, 2,000 mg, or 3,000 mg/day, given in 2 divided doses, with a treatment duration of up to 18 weeks.
Pri odraslih je bila učinkovitost levetiracetama dokazana v 3 dvojno slepih, s placebom kontroliranih študijah z odmerki 1.000 mg, 2.000 mg ali 3.000 mg/dan, uporabljenih v dveh deljenih odmerkih, in s trajanjem zdravljenja do 18 tednov.
• diplopia (double vision), vision blurred;
• diplopija (dvojni vid), zamegljen vid
Rhabdomyolysis and blood creatine phosphokinase increased*
mialgija rabdomioliza in zvišanje kreatin fosfokinaze v krvi*
Levetiracetam can be used during pregnancy, only if after careful assessment it is considered necessary by your doctor.
Levetiracetam se lahko med nosečnostjo uporablja samo, če zdravnik po skrbnem pretehtanju ugotovi, da je to potrebno.
Oral absolute bioavailability is close to
Absolutna peroralna biološka uporabnost je skoraj 100 %.
There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam.
Opisani so bili posamezni primeri zmanjšane učinkovitosti levetiracetama, če je bilo sočasno s peroralnim levetiracetamom uporabljeno osmotsko odvajalo makrogol.
The apparent body clearance of both levetiracetam and of its primary metabolite is correlated to the creatinine clearance.
Navidezni telesni očistek levetiracetama in njegovega primarnega presnovka je koreliral z očistkom kreatinina.
The patients were randomized to carbamazepine CR 400 - 1,200 mg/day or levetiracetam 1,000 - 3,000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.
Bolniki so bili randomizirani na karbamazepin CR od 400 do 1.200 mg/dan ali na levetiracetam od 1.000 do 3.000 mg/dan, zdravljenje pa je trajalo do 121 tednov, odvisno od odziva.
The active substance, levetiracetam, is a pyrrolidone derivative (S-enantiomer of α-ethyl-2-oxo-1pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances.
Zdravilna učinkovina levetiracetam je pirolidinski derivat (S-enantiomer α-etil-2-okso-1pirolidinacetamida) in kemično ni soroden obstoječim antiepileptičnim učinkovinam.
At 3,600 mg/kg/day, in only one of the 2 EFD studies, there was a slight decrease in foetal weight associated with a marginal increase in skeletal variations/minor anomalies.
Pri odmerku 3.600 mg/kg/dan so samo v eni od obeh študij embrio-fetalnega razvoja ugotovili rahlo zmanjšanje plodove mase v povezavi z mejnim povečanjem skeletnih sprememb/manjših anomalij.
• amnesia (loss of memory), memory impairment (forgetfulness), abnormal coordination/ataxia
• amnezija (izguba spomina), oslabljen spomin (pozabljivost), poslabšana koordinacija/ataksija
In this study, patients were prescribed 20 mg/kg, 25 mg/kg, 40 mg/kg or 50 mg/kg daily dose of oral solution based on their age titration schedule.
V tej študiji so bolnikom predpisali dnevni odmerek peroralne raztopine 20 mg/kg, 25 mg/kg, 40 mg/kg ali 50 mg/kg na podlagi sheme titriranja za njihovo starost.
Furthermore, levetiracetam has been shown in in vitro studies to bind to a specific site in rodent brain tissue.
Razen tega so študije in vitro pokazale, da se levetiracetam veže na specifično mesto v možganskem tkivu glodalcev.
43.6% of the levetiracetam treated patients and 19.6% of the patients on placebo were considered as responders.
Kot odzivnih je bilo ocenjenih 43,6 % prejemnikov levetiracetama in 19,6 % prejemnikov placeba.
What you need to know before you take Levetiracetam Actavis Group Do not take Levetiracetam Actavis Group
Kaj morate vedeti, preden boste vzeli zdravilo Levetiracetam Actavis Group Ne jemljite zdravila Levetiracetam Actavis Group
In order to ensure the accuracy of the dosing, this presentation should be prescribed for infants and young children aged from 6 months to less than 4 years.
Da bi zagotovili točnost odmerjanja, je treba to pakiranje predpisati dojenčkom in majhnim otrokom v starosti od 6 mesecev do manj kot 4 leta.
Therefore there is no need for plasma level monitoring of levetiracetam.
Zato koncentracije levetiracetama v plazmi ni treba kontrolirati.
Pull the plunger down and fill the syringe with a quantity of solution slightly beyond the prescribed dose (Figure 5).
Potegnite bat dol in napolnite brizgo s količino raztopine, ki je malenkost večja od predpisanega odmerka (slika 5).
Instruction for use: Instruction for use for 10 ml syringes
Navodilo za uporabo 10-ml brizg
A significant correlation between saliva and plasma concentrations has been shown in adults and children (ratio of saliva/plasma concentrations ranged from 1 to 1.7 for oral tablet formulation and after 4 hours post-dose for oral solution formulation).
Pri odraslih in otrocih so ugotovili pomembno korelacijo med koncentracijo v slini in plazmi (razmerje koncentracij slina/plazma je segala od 1 in 1,7 za peroralne tablete in za peroralno raztopino 4 ure po odmerku).
No new safety concerns for levetiracetam were identified for infants less than 12 months of age with epilepsy.
Pri dojenčkih z epilepsijo, mlajših od 12 mesecev niso ugotovili nobenih novih pomislekov glede varnosti za levetiracetam.
In patients aged 1 month to less than 4 years, a total of 190 patients have been treated with levetiracetam in placebo-controlled and open label extension studies.
Skupno 190 bolnikov, starih od 1 meseca do manj kot 4 leta, so zdravili z levetiracetamom v s placebom nadzorovanih in odprtih, razširjenih študijah.
This finding suggests that the interaction between levetiracetam and the synaptic vesicle protein 2A seems to contribute to the antiepileptic mechanism of action of the medicinal product.
Ta izsledek kaže, da bi interakcija med levetiracetamom in sinaptično vezikularno beljakovino 2A lahko pripomogla k antiepileptičnemu mehanizmu delovanja tega zdravila.
Peak plasma concentration was observed 0.5 to 1.0 hour after dosing.
Največja koncentracija v plazmi je bila dosežena od 0,5 do 1,0 uro po uporabi.
Levetiracetam Actavis Group is used: on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy.
Zdravilo Levetiracetam Actavis Group se uporablja: • sàmo za zdravljenje pri odraslih in mladostnikih od 16. leta starosti z novodiagnosticirano epilepsijo, za zdravljenje določene oblike epilepsije.
The mean total body clearance was 0.96 ml/min/kg.
Povprečni skupni telesni očistek je 0,96 ml/min/kg.
What Levetiracetam Actavis Group is and what it is used for What you need to know before you take Levetiracetam Actavis Group How to take Levetiracetam Actavis Group Possible side effects
Kaj je zdravilo Levetiracetam Actavis Group in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Levetiracetam Actavis Group Kako jemati zdravilo Levetiracetam Actavis Group
Add-on therapy for infants aged 6 to 23 months, children (2 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg
Dodatno zdravljenje dojenčkov, starih od 6 do 23 mesecev, otrok (v starosti od 2 do 11 let) in mladostnikov (v starosti od 12 do 17 let) s telesno maso manj kot 50 kg
Open the bottle and push the syringe adaptor firmly into the bottle neck (Figure 1).
Odprite stekleničko in nastavek brizge trdno potisnite v vrat stekleničke (slika 1).
For children aged 6 months to less than 4 years
Za otroke, stare od 6 mesecev do manj kot 4 leta
1,500 mg twice daily (1) Children 25 kg or less should preferably start the treatment with Levetiracetam Actavis Group
1.500 mg dvakrat na dan (1) Pri otrocih s telesno maso 25 kg ali manj je treba zdravljenje po možnosti začeti z zdravilom
The in vitro data and in vivo interaction data on oral contraceptives, digoxin and warfarin indicate that no significant enzyme induction is expected in vivo.
Podatki in vitro in podatki o medsebojnem delovanju s peroralnimi kontraceptivi, digoksinom in varfarinom in vivo kažejo, da in vivo ni pričakovati bistvene indukcije encimov.
In both population pharmacokinetic analyses, there was about a 20% increase of apparent clearance of levetiracetam when it was co-administered with an enzyme-inducing antiepileptic medicinal product.
V obeh populacijskih farmakokinetičnih analizah se je navidezni očistek levetiracetama v primeru sočasne uporabe s kakšnim antiepileptičnim zdravilom, ki inducira encime, povečal za približno 20 %.
Dose in children and adolescents 50 kg or more is the same as in adults.
Odmerek za otroke in mladostnikih s telesno maso 50 kg ali več je enak kot za odrasle.
In this study, the patients received levetiracetam as a fixed dose of 60 mg/kg/day (with twice a day dosing).
V tej študiji so bolniki prejemali stalen odmerek levetiracetama 60 mg/kg/dan (uporaba dvakrat na dan).
• weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic (anaphylactic) reaction;
• šibkost, vrtoglavico ali omotico ali težave z dihanjem, saj so to lahko znaki resne alergijske